Risk Score of Harigai et al for Pneumocystis Pneumonia in a Patient with Rheumatoid Arthritis Treated with Infliximab
Purpose: To determine the risk of pneumocystis pneumonia in a patient with rheumatoid arthritis being treated with infliximab using the score of Harigai et al.
Harigai et al identified risk factors associated with cumulative risk of a patient with rheumatoid arthritis being treated with infliximab developing pneumocystis pneumonia. The authors are from the Tokyo Medical and Dental University.
Patient population: Japanese with rheumatoid arthritis
Parameters:
(1) age of the patient
(2) concurrent daily dose of prednisolone (or equivalent)
(3) underlying lung disease
Parameter
Finding
Points
age of the patient
< 65 years of age
0
>= 65 years of age
1
concurrent daily dose of prednisolone
0 to 5 mg
0
>= 6 mg
1
underlying lung disease
absent
0
present
1
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the greater the risk of developing pneumocystis pneumonia.
Score
Cumulative Risk at 6 Months
Cumulative Risk at 1 Year
Cumulative Risk at 2 Years
0
4%
4%
4%
1
15%
15%
22%
2
54%
54%
76%
3
83%
83%
83%
To read more or access our algorithms and calculators, please log in or register.
Purpose: To determine the risk of pneumocystis pneumonia in a patient with rheumatoid arthritis being treated with infliximab using the score of Harigai et al.
